- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01400815
Randomized Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid
A Prospective, Double-blind, Randomized, Active Controlled, Parallel Group, Multicenter Phase II Clinical Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid
A randomized, active controlled clinical trial in which a total of 216 healthy smokers will be enrolled and followed over approximately 19 weeks.
The trial will evaluate the efficacy and safety of using X-22 as a smoking cessation aid.
Healthy smokers who plan to quit smoking will be screened for eligibility. Subjects will be randomized in a 1:1 ratio to 1 of the 2 treatment arms:
- Group 1: X-22 Cigarettes (very low nicotine)
- Group 2: Active Control Cigarettes The randomization will be stratified by gender. Efficacy will be assessed by analysis of cigarette consumption using self-report diaries and measurement of exhaled carbon monoxide (CO) and cotinine concentrations.
Safety will be assessed by evaluation of adverse events, physical examinations, clinical laboratory tests, and measurement of heart rate, blood pressure, and body weight at each study visit.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95816
- Benchmark Research Sacramento
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- Benchmark Research New Orleans
-
-
Texas
-
Austin, Texas, United States, 78705
- Benchmark Research Austin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible for participation in this study.
- Subjects must be considered by the investigator to be in general good health and between 18 and 65 years of age, inclusive.
- Subjects must have a history of smoking at least 10 cigarettes per day for at least 1 year, with less than 3 months of abstinence during the past year, and a continuous smoking history for at least 3 months prior to study entry.
- Subjects must indicate that they plan to quit smoking within the next 3 months.
- Subjects must have a CO measurement of ≥ 10 ppm at screening and baseline (Visit 1 and Visit 2).
- Subjects must be willing and able to return for scheduled follow-up examinations for a total of 5 months.
- Female subjects must have been postmenopausal for the previous 6 months or be surgically sterile, or must have a negative pregnancy test and use one of the following acceptable methods of birth control for the duration of the study and for at least 3 months prior to screening:
- abstinence, meaning a total lack of sexual activity,
- oral contraceptives ("the pill"),
- contraceptive injections,
- intrauterine device,
- double-barrier method (diaphragm or condom plus spermicidal cream),
- contraceptive patch, hormonal implant, hormonal vaginal ring, or
- male partner sterilization at least 3 months prior to screening. 7. Subjects must sign and be given a copy of the written Informed Consent form. 8. Subjects must be able to read, understand and complete the questionnaires independently.
Exclusion Criteria:
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.
- Subjects who have a household member who is already enrolled in this trial.
- Subjects who have attempted to quit smoking using one or more FDA-approved smoking cessation products (eg, nicotine replacement therapy [NRT] including nicotine gum, nicotine lozenges, nicotine patches, nicotine nasal spray, or nicotine inhaler; Zyban [bupropion]; or Chantix [varenicline]) for longer than 1 week in the past 3 months.
- Subjects who have been enrolled in another structured smoking cessation program (e.g., behavioral modification, hypnosis, acupuncture, or other alternative therapies) in the last 30 days.
- Subjects who have been in another smoking cessation trial in the past 6 months.
- Subjects who regularly use (greater than once per month) tobacco-based products other than cigarettes (eg, chew, snuff, snus, shisha, etc.).
- Subjects with a history of coronary artery disease, myocardial infarction, stroke, chronic obstructive pulmonary disease, or other significant pulmonary diseases. Controlled hypertensive subjects and mild asthmatics whose disease is controlled only with an as-needed inhaled beta agonist are acceptable.
- Subjects with a history of cancer within the past 60 months other than basal cell carcinoma.
- Subjects with a history of thromboembolic disease or taking warfin or any other anticoagulant, or anti-platelet drug such as clopidogrel (Plavix®) or pentoxifylline (Trental®). Low dose aspirin therapy is acceptable.
- Subjects with screening laboratory abnormalities that are considered by the investigator to be clinically significant.
- Subjects with a body mass index (BMI) >35.
- Subjects with poorly controlled diabetes or insulin-dependent diabetes.
- Subjects with other known serious pathophysiology or topical or systemic disorders of any kind that would confound the results of the study.
- Subjects with screening ECG abnormalities that are considered by the investigator to be clinically significant.
- Subjects who have used any illegal drug in the past 3 months.
- Subjects who have a positive urine drug screening result.
- Subjects who are pregnant or lactating, or who plan to become pregnant during the course of the study.
- Subjects participating in any other clinical trial of an investigational drug or device during the time of this clinical investigation or within 30 days prior to Screening visit.
- Subjects taking anti-depressants, anti-psychotics, clonidine, or any of the classes of drugs listed in the RapidCHECK® 12 Panel in the last 60 days (see Section 12.1.1).
- Subjects with systolic blood pressure over 140 mmHg and/or diastolic blood pressure over 90 mmHg.
- Subjects consuming an average of 3 or more drinks of alcohol per day.
- Subjects consuming greater than an average of 2 packs of cigarettes per day.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: X-22 Smoking Cessation Product
The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.
|
The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes. Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period. |
Active Comparator: Active Control Cigarette
The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional "light" cigarette.
|
The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional "light" cigarette. Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy - 4 Weeks of Continuous Abstinence From Smoking Cigarettes
Time Frame: Weeks 7 and 9 = telephone call, Week 8 = visit 6 and Week 10 = visit 7
|
The primary efficacy measurement is the number of subjects with 4 weeks of continuous abstinence from smoking cigarettes (Weeks 7-10), as assessed by subject diary and confirmed by exhaled carbon monoxide (CO), after treatment termination, at Visits 6 and 7. A responder: did not smoke and had less than 10 ppm exhaled CO. |
Weeks 7 and 9 = telephone call, Week 8 = visit 6 and Week 10 = visit 7
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- X-22-201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
-
University of Wisconsin, MadisonCentiment LLCCompletedSmoking | Smoking CessationUnited States
-
Yale UniversityCompletedSmoking | Smoking CessationUnited States
-
Johns Hopkins UniversityMaryland Department of Health and Mental HygieneCompletedCOach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation (C2Q)Smoking | Smoking CessationUnited States
Clinical Trials on X-22 Smoking Cessation Product
-
Oregon Research Behavioral Intervention Strategies...RecruitingTobacco UseUnited States
-
The University of Hong KongCompletedSmoking CessationHong Kong
-
Washington University School of MedicineCompleted
-
University of Missouri, Kansas CityCompleted
-
The University of Hong KongNot yet recruiting
-
ImbioNational Cancer Institute (NCI); Mayo Clinic; University of Michigan; University... and other collaboratorsCompleted
-
Oulu University HospitalActive, not recruiting
-
Kimber Richter, PhD, MPH, MANational Heart, Lung, and Blood Institute (NHLBI)CompletedSmokingUnited States
-
University of Wisconsin, MadisonCompletedSmoking | Tobacco Use DisorderUnited States
-
London South Bank UniversityNHS Lambeth; NHS Southwark CCG; Allen Carr EasywayCompleted